ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Tuesday, November 14, 2023

2:00PM-3:30PM: Abstract Number: 2488

Efficacy and Safety of ABBV-599 High Dose (Elsubrutinib 60 mg and Upadacitinib 30 mg) and Upadacitinib Monotherapy for the Treatment of Systemic Lupus Erythematosus: A Phase 2, Double-blind, Placebo-controlled Trial

Abstracts: SLE – Treatment II: Nonrenal

2:00PM-3:30PM: Abstract Number: 2463

Efficacy and Safety of Car-T-Cell Treatment in Refractory Antisynthetase Syndrome – Data of the First Three Patients

Abstracts: Muscle Biology, Myositis & Myopathies – Basic & Clinical Science I

2:00PM-3:30PM: Abstract Number: 2475

Elevation of the IL-17 Cytokine Family Distinguishes Kawasaki Disease from Other Pediatric Inflammatory Disorders

Abstracts: Pediatric Rheumatology – Clinical III: Potpourri

2:00PM-3:30PM: Abstract Number: 2454

Endometriosis Increase Risk of Antiphospholipid Syndrome: A Propensity Score Matched Cohort Study

Abstracts: Epidemiology & Public Health II

2:00PM-3:30PM: Abstract Number: 2497

Factors Influencing Time to Diagnosis in U.S. Patients with Systemic Lupus Erythematosus

Abstracts: Interprofessional OA & Lupus

2:00PM-3:30PM: Abstract Number: 2450

Gene by Respiratory Disease Interactions Associated with Developing Rheumatoid Arthritis

Abstracts: Epidemiology & Public Health II

2:00PM-3:30PM: Abstract Number: 2460

Health Care Segregation, but Not Metropolitan Area Segregation, Magnifies Racial Disparities in Hospital Outcomes of Pediatric Lupus

Abstracts: Healthcare Disparities in Rheumatology

2:00PM-3:30PM: Abstract Number: 2471

Higher Pain and Functional Impairment in Erosive Hand Osteoarthritis Than in Treated Rheumatoid Arthritis: A Comparative Study Between DIGICOD and ESPOIR Cohorts

Abstracts: Osteoarthritis II: Novel Insights from Observational Studies

2:00PM-3:30PM: Abstract Number: 2496

HXB-319, a New Generation Mesenchymal Stromal Cell (MSC) Therapy, Alleviates Neutrophilic Inflammation, and End-organ Damage in Pulmonary Renal Syndromes by Inducing FoxP3+ Tregs, and by Promoting TNFα-stimulated gene-6 (TSG-6) over Expression

Abstracts: Vasculitis – ANCA-Associated II

2:00PM-3:30PM: Abstract Number: 2499

Influence of Adiposity on Physical Function, Physical Activity, and Self-Reported Symptom Severity for Individuals with Arthritis Prior to Beginning a Physical Activity Promotion Intervention

Abstracts: Interprofessional OA & Lupus

2:00PM-3:30PM: Abstract Number: 2431

Integrated Single Cell Multi-omics Analysis in At-Risk for Future Rheumatoid Arthritis (RA) and Early RA Reveals Shared Transcription Factor Profiles in Multiple Cell Lineages

Abstracts: RA – Etiology & Pathogenesis

2:00PM-3:30PM: Abstract Number: 2447

Interleukin-6 Activates Glial Cells and Induces Cognitive Dysfunction in Murine Neuropsychiatric Lupus

Abstracts: SLE – Animal Models

2:00PM-3:30PM: Abstract Number: 2446

Intermittent Fasting Attenuates Cognitive Dysfunction in Murine Systemic Lupus Erythematosus

Abstracts: SLE – Animal Models

2:00PM-3:30PM: Abstract Number: 2433

Longitudinal Multi-Omics Single Cell Analysis Reveals Abatacept Treatment Shifts Peripheral Lymphocyte Subpopulations in Seropositive RA with Reduction of Mature B Cells and Retention of Transitional and Naive B Cells

Abstracts: RA – Etiology & Pathogenesis

2:00PM-3:30PM: Abstract Number: 2470

Low Serum Adiponectin Levels Were Associated with Radiographic Progression of Hand Osteoarthritis in a 6-year Follow-up of the Dong-gu Study

Abstracts: Osteoarthritis II: Novel Insights from Observational Studies

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].